

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization

International Bureau

(43) International Publication Date  
23 June 2022 (23.06.2022)



(10) International Publication Number  
**WO 2022/129637 A1**

(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 35/00 (2006.01)  
C07K 16/32 (2006.01) A61P 37/00 (2006.01)  
C07K 16/30 (2006.01)

(21) International Application Number:

PCT/EP2021/086843

(22) International Filing Date:

20 December 2021 (20.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20306608.9 18 December 2020 (18.12.2020) EP  
PCT/EP2021/086556  
17 December 2021 (17.12.2021) EP  
EP21306822.4 17 December 2021 (17.12.2021) EP

(71) Applicants: **ABLYNX NV** [BE/BE]; Technologiepark 21,  
9052 Zwijnaarde (BE). **SANOBI** [FR/FR]; 54 rue La  
Boétie, 75008 Paris (FR).

(72) Inventors: **NEYT, Katrijn**; c/o Ablynx N.V., Patent De-  
partment, Technologiepark 21, 9052 Zwijnaarde (BE).  
**ROOBROUCK, Annelies**; c/o Ablynx N.V., Patent De-  
partment, Technologiepark 21, 9052 Zwijnaarde (BE).  
**STAELENS, Stephanie**; c/o Ablynx N.V., Patent De-  
partment, Technologiepark 21, 9052 Zwijnaarde (BE).  
**VAN BELLE, Tom**; c/o Ablynx N.V., Patent Depart-  
ment, Technologiepark 21, 9052 Zwijnaarde (BE). **VER-  
HELST, Judith**; c/o Ablynx N.V., Patent Department,  
Technologiepark 21, 9052 Zwijnaarde (BE). **DULLAERS,  
Melissa**; c/o Ablynx N.V., Patent Department, Technolo-  
giepark-Zwijnaarde 21, 9052 Gent (BE).

(74) Agent: **HOFFMANN EITLE PATENT- UND  
RECHTSANWÄLTE PARTMBB, ASSOCIATION  
NO. 151**; Arabellastraße 30, 81925 Munich (DE).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,  
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,  
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,  
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,  
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))  
— before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments (Rule 48.2(h))  
— with sequence listing part of description (Rule 5.2(a))

(54) Title: T CELL RECRUITING POLYPEPTIDES BASED ON TCR ALPHA/BETA REACTIVITY

(57) Abstract: The present technology provides T cell recruiting polypeptides that specifically bind to the constant domain of a human and of a non-human primate TCR. The present technology also provides nucleic acids, vectors, and compositions. The polypeptides can be used in methods for treatment of cancer.

WO 2022/129637 A1